























Previously, we have demonstrated that cancer stem cells 
(CSCs) critically rely on mitochondrial biogenesis and 
oxidative metabolism for their propagation [1, 2]. 
Doxycycline, a tetracycline-based antibiotic, is a known 
inhibitor  of   the  small  mitochondrial   ribosome  (28S)  
 
and, as a consequence, is an inhibitor of mitochondrial 
protein translation [1-4]. Indeed, in vitro and in vivo 
evidence supports the potential inhibitory effects of 
Doxycycline on cancer growth through inhibition of 
CSC propagation [1-5]. More specifically, we demons-
trated that Doxycycline inhibits CSC propagation, as 
assessed using the 3D mammosphere assay, with an IC-
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involving  two  FDA‐approved  antibiotics  and  a  dietary  vitamin  supplement.  This  approach was  designed  to
induce a “rho‐zero‐like” phenotype in cancer cells. This strategy effectively results in the synergistic eradication
of  CSCs,  using  vanishingly  small  quantities  of  two  antibiotics.  The  2  metabolic  targets  are  i)  the  large
mitochondrial ribosome and ii) the small mitochondrial ribosome. Azithromycin inhibits the large mitochondrial
ribosome as an off‐target side‐effect. In addition, Doxycycline inhibits the small mitochondrial ribosome as an
off‐target  side‐effect.    Vitamin  C  acts  as  a  mild  pro‐oxidant,  which  can  produce  free  radicals  and,  as  a
consequence,  induces mitochondrial biogenesis. Remarkably, treatment with a combination of Doxycycline (1
μM), Azithromycin (1 μM) plus Vitamin C (250 μM) very potently inhibited CSC propagation by >90%, using the
MCF7  ER(+)  breast  cancer  cell  line  as  a  model  system.  The  strong  inhibitory  effects  of  this  DAV  triple
combination therapy on mitochondrial oxygen consumption and ATP production were directly validated using
metabolic  flux  analysis.  Therefore,  the  induction  of mitochondrial  biogenesis  due  to mild  oxidative  stress,
coupled with  inhibition of mitochondrial protein translation, may be a new promising therapeutic anti‐cancer
strategy. Consistent with these assertions, Vitamin C is known to be highly concentrated within mitochondria,
by a specific  transporter, namely SVCT2,  in a sodium‐coupled manner. Also,  the concentrations of antibiotics
used here represent sub‐antimicrobial  levels of Doxycycline and Azithromycin, thereby avoiding the potential
problems  associated with  antibiotic  resistance.  Finally, we  also  discuss  possible  implications  for  improving
health‐span and  life‐span, as Azithromycin  is an anti‐aging drug that behaves as a senolytic, which selectively
kills and removes senescent fibroblasts.  
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50 between 2-to-10 μM, specifically in MCF7 cells, an 
ER(+) human breast cancer cell line [1, 2]. Importantly, 
quantitatively similar results were obtained with several 
other human breast cancer cell lines, such as T47D 
[ER(+)] and MDA-MB-231 (triple-negative).  
 
Recently, the Antibiotics for Breast Cancer (ABC) trial 
was conducted at The University of Pisa Hospital [5]. 
The ABC trial aimed to assess the anti-proliferative and 
anti-CSC mechanistic actions of Doxycycline in early 
breast cancer patients [5]. The primary endpoint of the 
ABC trial was to determine whether short-term (2 
weeks) pre-operative treatment with oral Doxycycline 
of stage I-to-III early breast cancer patients resulted in 
inhibition of tumor proliferation markers, as determined 
by a reduction in tumor Ki67 from baseline (pre-
treatment) to post-treatment, at the time of surgical 
excision [5]. Secondary endpoints were used to 
determine if pre-operative treatment with Doxycycline 
in the same breast cancer patients resulted in inhibition 
of CSC propagation and a reduction of mitochondrial 
markers. 
 
A pilot study of the ABC trial demonstrated that 
Doxycycline treatment successfully decreased the 
expression of CSC markers in breast cancer tumor 
samples. Post-doxycycline tumor samples demonstrated 
a statistically significant 40% decrease in the stemness 
marker CD44, when compared to pre-Doxycycline 
tumor samples [5].  
 
CD44 levels were reduced between 17.65% and 
66.67%, in 8 out of 9 patients treated with Doxycycline 
[5]. In contrast, only one patient showed a rise in CD44, 
by 15%. This represents a nearly 90% positive response 
rate. Similar results were also obtained with ALDH1 
[5], another marker of stemness, especially in HER2(+) 
patients. In contrast, markers of mitochondria, pro-
liferation, apoptosis and neo-angiogenesis, were all 
similar between the two groups. These results suggest 
that Doxycycline can selectively eradicate CSCs in 
breast cancer patients in vivo [5]. 
 
Given these promising results in the ABC pilot study, 
here we aimed to further potentiate the efficacy of 
Doxycycline, for patient benefit. Our preliminary in 
vitro results indicate that the inhibitory effects of 
Doxycycline on CSC propagation can be further 
potentiated, by employing a combination therapy 
strategy, with two additional pharmacological agents, 
namely i) Azithromycin and ii) Vitamin C. 
Azithromycin inhibits the large mitochondrial ribosome, 
as an off-target side-effect. Vitamin C acts as a mild 
pro-oxidant, which can produce free radicals and, as a 
consequence, induces mitochondrial biogenesis.  
This combination therapy was designed to stimulate 
mitochondrial biogenesis, while simultaneously 
inhibiting mitochondrial protein translation, resulting in 
functional ATP depletion. This occurs because inhibi-
tion of mitochondrial protein translation effectively 
blocks the production of proteins encoded by 
mitochondrial DNA (mt-DNA), which are absolutely 
required for OXPHOS, thereby creating a “rho-zero-
like” phenotype. Since Azithromycin is an established 
inducer of autophagy, this strategy should also stimulate 
mitophagy, to actively eliminate defective mito-
chondria. This functional property of Azithromycin may 




Combining two complementary inhibitors of 
mitochondrial protein translation at a low-dose: 
Doxycycline and Azithromycin 
 
Here, we experimentally evaluated if the inhibitory 
effect of Doxycycline on mammosphere formation 
could be potentiated, by a combination with Azithro-
mycin. To this end, Doxycycline and Azithromycin 
were tested alone or in combination at low concen-
trations.  
 
Figure 1 shows that at low concentrations (0.1 μM and 1 
μM) Doxycycline and Azithromycin alone had little or 
no effect on the inhibition of mammosphere formation. 
However, the combination of 1 μM Doxycycline and 1 
μM Azithromycin exerted a very significant inhibitory 
effect on mammosphere formation.  
 
Note that in combination, Doxycycline and Azithro-
mycin display a marked increased efficacy in the 
inhibition of mammosphere formation, relative to when 
the drugs are used alone (the IC-50 for the combination 
is lower than for Azithromycin alone and lower than for 
Doxycycline alone, when both agents are used 
individually). These results suggest that a com-bination 
of Doxycycline and Azithromycin might have more 
therapeutic efficacy, than the two drugs used alone.  
 
To evaluate if the inhibitory effects on mammosphere 
formation of this double combination is related to 
mitochondrial function, we next examined the meta-
bolic profile of MCF7 cell monolayers pre-treated with 
the combination of 1 μM Doxycycline and 1 μM 
Azithromycin or with the same drugs alone for 3-days. 
Interestingly, the rates of both oxidative mitochondrial 
metabolism and glycolysis were significantly reduced 
by the DOX-AZI combination pre-treatment, as 
assessed using the Seahorse XFe96 analyzer. This 
resulted in significant reductions in respiration (basal 
and maximal), as well as reduced ATP levels (Figure 2).  
























































































































www.aging‐us.com  2205  AGING 
Similarly, both glycolysis and glycolytic reserve were 
decreased by the DOX-AZI combination (Figure 3). 
Finally, as seen in Figure 4, MCF7 cancer cells were 
shifted from a highly energetic profile to a meta-
bolically quiescent state. However, the combination of 1 
μM Doxycycline with 1 μM Azithromycin is initially 


















































ditions (Figure 5).  
 
Taken together, these results indicate that the combina-
tion of low-dose Doxycycline with Azithromycin might 
be a more efficacious therapeutic option than Doxy-
cycline alone for the eradication of CSCs, by inhibition 





















































bolically  quiescent  state.  We  examined  the  metabolic  profile  of  MCF7  cell  monolayers  pre‐treated  with  the  combination  of
Doxycycline (1 μM) and Azithromycin (1 μM) for 3 days, using the Seahorse XFe96 analyzer. *p < 0.05. DOX, Doxycycline; AZI, Azithromycin. 
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Combining two inhibitors of mitochondrial protein 
translation, with a pro-oxidant:  Doxycycline and 
Azithromycin Plus Vitamin C (DAV) 
 
Our results indicate that a combination of Doxycycline 
and Azithromycin is more efficacious than the 
individual antibiotics in inhibiting CSCs propagation. 
Thus, we sought to test the hypothesis that a triple 
combination of Doxycycline, Azithromycin and 
Vitamin C could more potently inhibit CSC propaga-
tion. We have previously shown that Vitamin C alone 






























Importantly, simultaneous treatment with 1 μM 
Doxycycline, 1 μM Azithromycin and 250 μM Vitamin 
C very potently inhibited CSC propagation by ~90% 
(Figure 6). Thus, near complete ablation of 3D tumor-
sphere forming ability was achieved at very low 
concentrations of these two antibiotics, suggesting that 
this DAV triple combination targets CSCs at a 
vulnerable weak point.  
 
Next, we evaluated the potential inhibitory effects of the 
DAV triple combination on mitochondrial function, by 
determining the metabolic profile of MCF7 cell 
monolayers pre-treated with a combination of 1 μM 
Doxycycline, 1 μM Azithromycin and 250 μM Vitamin 
C for 3-days. Remarkably, the rate of oxidative mito-
chondrial metabolism was reduced by >50% and ATP 
levels were drastically reduced (by >90%), as assessed 
using the Seahorse XFe96 analyzer. Overall, this resulted 
in significant reductions in both basal and maximal 
respiration (Figures 7 and 8).  In contrast, glycolysis 
was increased, while glycolytic reserve was decreased 





























Finally, as seen in Figure 9 and 10, treatment with 250 
μM Vitamin C alone, significantly increased both 
mitochondrial metabolism and glycolysis in MCF7 
cancer cells. These observations are consistent with the 
idea that Vitamin C alone acts as a mild pro-oxidant and 
stimulates mitochondrial biogenesis, driving increased 
mitochondrial metabolism and elevated ATP 
production. This interpretation is consistent with our 
experimental data directly showing that the inclusion of 
two inhibitors of mitochondrial protein translation with 
Vitamin C, blocks and completely reverses this Vitamin 
C induced increase in mitochondrial oxidative 
metabolism (Figures 11 and 12).  
 
Taken together, our evidence supports a novel 
combined metabolic strategy to better eradicate CSCs. 
More specifically, we demonstrate that the inhibitory 
effects of Doxycycline on the CSC population can be 
potentiated by combination with another FDA-approved 
antibiotic, Azithromycin, and a dietary supplement, 
namely Vitamin C (a mild pro-oxidant).   
Figure 5. The Doxycycline  (1 μM) plus Azithromycin  (1
μM)  combination  is  initially  non‐toxic  under
anchorage‐independent  growth  conditions.  MCF7  cells
were  first  treated  with  the  combination  for  48  hours,  as
monolayers,  and  then  they  were  trypsinized  and  re‐seeded
onto  low‐attachment  plates  for  12  hours,  before  they were
subjected to a live/dead assay. Note that the combination has




 Figure  6.  MCF7  3D  mammosphere  formation  is
extremely  sensitive  to  inhibition  by  combined  treat‐
ment with  Doxycycline  [1  μM],  Azithromycin  [1  μM] 
and  Vitamin  C  [250  μM]  (D+A+VitC).    Bar  graphs  are 
shown  as  the  mean  ±  SD,  t‐test,  two‐tailed.  Note  that 
approximately  90%  inhibition  was  observed  with  the  triple 
combination. ****p < 0.0001. 

















































































































graphs. Note  that  the  rate of oxidative mitochondrial metabolism was  reduced by >50% and ATP  levels were drastically  reduced by
>95%, as assessed using the Seahorse XFe96 analyzer. This resulted in significant reductions in both basal and maximal respiration. Note
also that glycolysis was increased, while glycolytic reserve was decreased by the triple combination. ***p < 0.001; ****p < 0.0001. 
Figure  7.  Combining  low‐dose  Azithromycin  and
Doxycycline  with  Vitamin  C  (DAV),  dramatically  inhibits
metabolism: Seahorse profiles. The metabolic profile of MCF7
cell  monolayers  pre‐treated  with  the  triple  combination  (1  μM
Doxycycline, 1 μM Azithromycin and 250 μM Vitamin C) for 3 days
was assessed using  the  Seahorse XFe96 analyzer.   Note  that  the
DAV  triple  combination  inhibits  oxidative  mitochondrial  meta‐
bolism  (measured  by  OCR)  and  induces  glycolytic  function
(measured by ECAR).  
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This new DAV therapeutic strategy should provide for 
the more efficient eradication of CSCs. We aim to test 
this hypothesis in future clinical trials.  
 
Evaluating the temporal Effects of pre-treatments on 
the efficacy of the DAV triple combination, using 
CSC propagation as a read-out 
 
We devised a system to test whether it was required for 
all three components of the DAV triple combination to 
be administered at the same time, by using a pre-
treatment strategy prior to initiating the 3D mammo-
sphere stem cell assay.  
 
Briefly, MCF7 cells, grown as monolayer cultures, were 









































or Doxycycline Plus Azithromycin (D + A; 1 μM each), 
for a period of 7 days. Then, MCF7 cells were harvested 
with trypsin and re-plated under anchorage-independent 
growth conditions, in the presence of various com-
binations of Vitamin C, Doxycycline and Azithro-
mycin.  
 
Figure 13 shows that 7 days of pre-treatment with either 
Vitamin C alone or Doxycycline Plus Azithromycin (D 
+ A), rendered the DAV triple combination significantly 
less effective. Therefore, it appears that to achieve 
maximal impact, all three components of the DAV 
triple combination of Doxycycline (1 μM), Azithro-
mycin (1 μM) and Vitamin C (250 μM), should be 















































































Mechanistically, it appears that these pre-treatments 
“pre-conditioned” MCF7 cells to the effects of the DAV 
triple combination.  This may be due to their ability to 





In this report, we provide evidence supporting a novel 
“synthetic-metabolic” approach to target CSCs, via a 
triple combination therapeutic strategy, which includes 
two clinically approved drugs and one essential vitamin. 
This therapeutic strategy drives the near complete 
elimination of CSC propagation, but only uses very 
minute amounts of these compounds. More speci-fically, 
this approach involves the simultaneous inhibition of two 
key targets, namely the large and small mito-chondrial 
ribosomes. Because mitochondria originally evolved 
from bacteria over 1.45 billion years, they still share 
certain conserved features related to protein translation. 
As a consequence, Azithromycin specifically blocks the 
function of the large mito-ribosome (39S), as an off-
target effect.  Similarly, Doxycycline inhibits the small 

































In contrast, Vitamin C functions as a mild pro-oxidant, 
producing free radicals. Here, we show that a triple 
combination of Doxycycline (1 μM), Azithromycin (1 
μM) and Vitamin C (250 μM) effectively blocked CSC 
propagation by ~90% (summarized in Figure 14). In this 
context, we used the ER(+) breast cancer cell line, 
namely MCF7, as an established model system for 
monitoring and quantitating the 3D propagation of 
CSCs.  Finally, we directly validated and confirmed that 
this DAV triple combination therapy potently inhibited 
mitochondrial oxygen consumption (OCR) and 
increased glycolytic flux (ECAR), as predicted.  Based 
on our current metabolic findings, we propose that this 
triple combination is a feasible and novel anti-cancer 
strategy for targeting CSCs.  
 
Cancer:  DAV combination therapy for targeting 
mitochondria in CSCs. 
  
 
Vitamin C is generally considered to be an anti-oxidant. 
However, depending on its relative concentration and 
cellular localization, Vitamin C can also act as a pro-












































The ascorbate radical is normally very stable, but it 
becomes more reactive especially in the presence of 
metal ions, including iron (Fe), allowing the ascorbate 
radical to become a much more powerful pro-oxidant. 
Therefore, we speculate that as mitochondria are par-
ticularly rich in iron, they could become a key target of 
the pro-oxidant effects of Vitamin C, driving mitochon-
drial oxidative stress and new mitochondrial biogenesis.  
 
Importantly, Vitamin C is highly concentrated within 
mitochondria [7-11]. For example, when U937 cells (a 
human leukaemia cell line) were incubated for only 15 
minutes in media containing 3 μM Vitamin C, it was 
very efficiently transported to the mitochondria, reaching 
a level of 5 mM – being concentrated ~1,700-fold [8]. 
Mitochondrial transport of Vitamin C is accomplished by 
the sodium-coupled Vitamin C transporter 2 (SVCT2) [7-
10], also known as SLC23A2, although other novel 






































This mitochondrial targeting of Vitamin C may directly 
explain the effects we observed here of the triple 
combination on CSCs, as we have previously shown 
that CSCs have a significantly increased mitochondrial 
mass [12, 13] and this contributes to their ability to 
undergo anchorage-independent growth [14, 15]. 
Hence, the use of inhibitors of mitochondrial protein 
translation, together with Vitamin C, would ultimately 
prevent CSC mitochondria from fully recovering from 
the pro-oxidant effects of Vitamin C, as these target 
cells would be unable to re-synthesize new functional 
mitochondria (Figure 15). Thus, under these meta-
bolically restricted conditions, cancer cells would be 
expected to undergo “frustrated” or “incomplete” 
mitochondrial biogenesis.  This assertion is directly 
supported by the Seahorse flux analysis data shown in 
Figures 11 and 12, revealing i) reduced mitochondrial 
metabolism, ii) increased compensatory glycolytic 
function, and iii) severe ATP depletion.  






















































































































graphs. Note  that  low‐dose Vitamin C  increases basal  respiration, ATP production and maximal  respiration, while  the DAV
triple combination decreases all three of these parameters. Also, note that low‐dose Vitamin C and the DAV triple combination
both increase glycolysis, while decreasing glycolytic reserve capacity. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
Figure 13. Effect of various pre‐treatments on  the efficacy of  the DAV  triple combination. Briefly, MCF7  cells, grown as
monolayer cultures, were first pre‐treated with either Vitamin C alone (250 μM), or Doxycycline Plus Azithromycin (D + A; 1 μM each),
for a period of 7 days. Then, MCF7 cells were harvested with trypsin and re‐plated under anchorage‐independent growth conditions, in








































































































Based on the mechanism(s) underpinning the strong 
effectiveness of the triple combination, other pro-
oxidants could also be potentially substituted for 
Vitamin C. As many current chemotherapeutic agents, 
as well as targeted radiation, all kill cancer cells, via 
their pro-oxidant actions, then combined inhibition of 
mitochondrial protein translation could be used as an 
add-on to conventional therapy and would be predicted 
to improve their efficacy. However, Vitamin C clearly 
has fewer side effects and a better safety profile than 
most standard chemotherapeutic agents.  Additional 
experimentation will be required to further test this 
intriguing hypothesis.  
 
Figure  14.  Summary  diagram  highlighting  the  mechanism(s)  of  action  related  to  the  triple  combination  of
Azithromycin, Doxycycline and Vitamin C. This approach effectively  results  in  the  synergistic eradication of CSCs, using
vanishingly  small  quantities  of  antibiotics.  It  is  important  to  note  Doxycycline  and  Azithromycin  are  not  direct  OXPHOS
inhibitors, but instead are inhibitors of mitochondrial protein translation. The 2 metabolic targets are the large mito‐ribosome
and the small mito‐ribosome. Azithromycin  inhibits the  large mitochondrial ribosome as an off‐target side‐effect.  In addition,
Doxycycline inhibits the small mitochondrial ribosome as an off‐target side‐effect. Vitamin C acts as a mild pro‐oxidant and can
stimulate the production of free radicals, driving mitochondrial biogenesis, secondary to mitochondrial oxidative stress and the
anti‐oxidant  response. Vitamin C  is  also  thought  to  act  as  an  inhibitor  of  the  glycolytic  enzyme GAPDH  (Glyceraldehyde  3‐
phosphate dehydrogenase). However, here, we did not observe any inhibition of glycolysis, when Vitamin C was tested alone.  
Figure 15. Anti‐mitochondrial therapy.  Vitamin C can act as a 
pro‐oxidant,  via  the  production  of  free  radicals.  The  ascorbate
radical is normally very stable, but becomes highly reactive  in the 
presence  of metal  ions,  including  iron  (Fe). As mitochondria  are 
rich  in  iron,  they  could  become  a  key  target  of  the  pro‐oxidant 
effects  of  Vitamin  C,  sequentially  driving  first  mitochondrial 
oxidative stress and then mitochondrial biogenesis. However, the 
use  of  inhibitors  of  mitochondrial  protein  translation,  together 
with Vitamin C, would ultimately prevent CSC mitochondria  from 
fully  recovering,  leading  instead  to  CSC  eradication.  Additional 
experimentation will be required to further test this hypothesis.  




































Previous studies have shown that Vitamin C by itself 
increases mitochondrial ATP production by up to 1.5-
fold, in the rat heart, under conditions of hypoxia [16]. 
In addition, Vitamin C is a positive regulator of endo-
genous L-carnitine biosynthesis, an essential micro-
nutrient that is required for mitochondrial beta-
oxidation [17, 18]. As such, these findings are consis-
tent with our current results showing that Vitamin C 
alone is indeed sufficient to increase mitochondrial ATP 
production, by up to 2-fold, in MCF7 cells (Figure 16).  
 
Aging: Improving health-span and life-span 
 
We believe that the DAV triple combination therapy 
that we describe here may also have implications for 
improving health-span and life-span, as aging is one of 
the most significant risk factors for the development of 
many human cancer types [19, 20]. Moreover, we have 
previously demonstrated that Azithromycin, by itself, is 




































vity, that targets and removes senescent fibroblasts, 
such as myo-fibrobasts, with great efficiency approach-
ing nearly 97% [21]. The accumulation of pro-inflam- 
matory senescent cells is thought to be the primary 
cause of many aging-associated diseases, such as heart 
disease, diabetes, dementia and cancer, to name only a 
few [21]. Since cancer-associated fibroblasts (CAFs) 
are senescent myo-fibroblasts, with tumor promoting 
activity, this triple combination approach with Azith-
romycin may also effectively target the glycolytic tumor 
stroma of aggressive and metastatic cancers, especially 
those bearing the metabolic hallmarks of the “Reverse 




In conclusion, Phase II clinical trials will be necessary 
to validate the potential therapeutic efficacy of the DAV 
triple combination, for eradicating CSCs, in breast 
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MATERIALS AND METHODS 
 
Cell lines and reagents 
 
MCF7 cells, an ER(+) human breast cancer cell line, was 
originally purchased from the American Type Culture 
Collection (ATCC), catalogue number HTB-22. Doxy-
cycline, Azithromycin and Ascorbic Acid (Vitamin C) 
were all obtained commercially from Sigma-Aldrich, Inc. 
 
Mammosphere formation assay 
 
A single cell suspension was prepared using enzymatic 
(1x Trypsin-EDTA, Sigma Aldrich, #T3924), and 
manual disaggregation (25 gauge needle) [12-15]. Cells 
were plated at a density of 500 cells/cm2 in 
mammosphere medium (DMEM-F12 + B27 + 20 ng/ml 
EGF + PenStrep) under non-adherent conditions, in 
culture dishes pre-coated with (2-hydroxyethylmetha-
crylate) (poly-HEMA, Sigma, #P3932), called “tumor-
sphere plates”. Vehicle alone (DMSO) control cells 
were processed in parallel. Cells were grown for 5 days 
and maintained in a humidified incubator at 37°C. After 
5 days of culture, 3D mammospheres >50 μm were 
counted using an eye piece (“graticule”), and the 
percentage of cells plated which formed spheres was 
calculated and is referred to as percent mammosphere 
formation efficiency (MFE) and was normalized to one 
(1 = 100% MFE). 
 
Metabolic flux analysis 
 
Real-time oxygen consumption rates (OCR) and 
extracellular acidification rates (ECAR) rates in MCF7 
cells were determined using the Seahorse Extracellular 
Flux (XFe96) analyzer (Seahorse Bioscience, USA) 
[29-31]. Briefly, 1.5 x 104 cells per well were seeded 
into XFe96 well cell culture plates, and incubated 
overnight to allow cell attachment. Then, cells were 
treated with antibiotics and/or Vitamin C for 72h. 
Vehicle-alone control cells were processed in parallel. 
After 72 hours of incubation, cells were washed in pre-
warmed XF assay media (or for OCR measurement, XF 
assay media sup-plemented with 10mM glucose, 1mM 
Pyruvate, 2mM L-glutamine and adjusted at 7.4 pH). 
Cells were then maintained in 175 µL/well of XF assay 
media at 37°C, in a non-CO2 incubator for 1 hour. 
During the incubation time, we loaded 25 µL of 80 mM 
glucose, 9 µM oligomycin, and 1M 2-deoxyglucose (for 
ECAR measurement) or 10 µM oligomycin, 9 µM 
FCCP, 10 µM rotenone, 10 µM antimycin A (for OCR 
measurement), in XF assay media into the injection 
ports in the XFe96 sensor cartridge. Measurements were 
normalized by protein content (SRB assay). Data sets 
were analyzed using XFe96 software and GraphPad 
Prism software, using one-way ANOVA and Student’s 
t-test calculations. All experiments were performed in 
quintuplicate, three times independently. 
 
Live/dead assay for anoikis-resistance 
 
Following monolayer treatment with either Doxycyline 
alone, Azithromycin alone or the combination for 48 
hours, the CSC population was enriched by seeding 
onto low-attachment plates [32]. Under these 
conditions, the non-CSC population undergoes anoikis 
(a form of apoptosis induced by a lack of cell-substrate 
attachment) and CSCs are believed to survive. The 
surviving CSC fraction was then determined by FACS 
analysis. Briefly, 1 × 104 MCF7 monolayer cells were 
treated with antibiotics or vehicle alone for 48h in 6-
well plates. Then, cells were trypsinized and seeded in 
low-attachment plates in mammosphere media. After 
12h, the MCF7 cells were spun down. Cells were rinsed 
twice and incubated with LIVE/DEAD dye (Fixable 
Dead Violet reactive dye; Invitrogen) for 10 minutes. 
Samples were then analyzed by FACS (Fortessa, BD 
Bioscence). The live population was then identified by 
employing the LIVE/DEAD dye staining assay. Data 
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